VivoSim Labs, Inc. (NASDAQ: VIVS) announced it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to raise approximately $4 million in gross proceeds through a private placement. The transaction involves the sale of 4,705,883 shares of common stock, or common stock equivalents, and accompanying warrants at a combined price of $0.85 per share. The warrants are exercisable following shareholder approval and expire five years after their initial exercise date, carrying an exercise price of $0.85 per share. Additionally, subject to shareholder approval, the company agreed to amend certain existing May 2024 warrants by reducing their exercise price from $9.60 to $0.85 per share.
The offering is expected to close on or about July 17, 2026, subject to customary closing conditions. VivoSim intends to use the net proceeds for working capital and general corporate purposes. The securities were offered in a private placement exempt from Securities Act registration requirements, and the company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission covering the shares and warrant shares issued in the transaction.
This capital raise is significant for VivoSim as it positions the company to advance its mission of providing testing of drugs and drug candidates using three-dimensional human tissue models of liver and intestine. The company offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models, which are gaining traction following the U.S. Food and Drug Administration's (FDA) roadmap to refine animal testing requirements in favor of non-animal methods. The FDA's push for NAM methods could accelerate adoption of human tissue models, potentially reducing reliance on traditional animal testing and streamlining drug development processes.
The implications of this announcement extend beyond VivoSim. If successful, the company's approach could lead to more accurate and ethical testing of pharmaceutical compounds, benefiting patients, researchers, and the broader biotechnology industry. The private placement also signals investor confidence in the company's technology and its alignment with regulatory trends. For the industry, the move underscores a shift toward innovative testing methodologies that may offer cost savings and improved predictive power for drug toxicity.
VivoSim Labs, based in San Diego, CA, continues to focus on its core business of human tissue modeling. The company anticipates that the FDA's evolving stance on animal testing will create new opportunities for its services. More information about VivoSim is available on its website at https://vivosim.ai/.
For further details on the press release, visit https://ibn.fm/7Ov0B.
